Synonyms: compound 4 [PMID: 28012176] | UE-2343 | Xanamem®
Compound class:
Synthetic organic
Comment: UE2343 is an oral, brain-penetrant hydroxysteroid 11-beta dehydrogenase 1 (11-βHSD1) inhibitor that was developed to reduce brain levels of the stress hormone cortisol, as a mechanism to improve memory in Alzheimer's disease patients [1-2]. It failed to provide efficacy in a phase 2 clinical trial.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
UE2343 was advanced to clinical trial, to evaluate its potential efficacy in patients with mild Alzheimer's disease. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02727699 | A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu) | Phase 2 Interventional | Actinogen Medical | The results from this study have been posted on ClinicalTrials.gov. UE2343 (Xanamen®) failed to show clinical benefit in patients with mild Alzheimer's dementia when compared to placebo. |